1 Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published. Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005

2 Joe Rappon, Jay Neitz, Maureen Neitz, Carol Chung, Thomas Walter Chalberg; Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408

3 A 36-month clinical trial demonstrated safety and efficacy for children ages six to 10 at enrolment, significantly reducing both axial length and cycloplegic SER progression versus the control. The study has been recognized for its rigor, designed as a prospective, randomized, controlled, subject and observer masked, multi-site, three-arm parallel group clinical trial with diverse subjects reflecting the U.S. population. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.

4 Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-42

5 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363


Please note that our products are not available for sale or distribution in every country in the world.
Our products are not available for sale in the U.S.